ENA Respiratory

Executive Summary

ENA Respiratory is an Australian clinical-stage biotechnology company developing INNA-051, a first-in-class small-molecule TLR2/6 agonist administered as a self-administered nasal dry-powder spray. The product primes innate immunity in the upper airway to accelerate viral clearance and prevent progression of respiratory viral infections, targeting at-risk populations. The company has raised $22.4 million to date and is currently in Phase 2 clinical development. INNA-051 has the potential to address a significant unmet need in respiratory infectious diseases by providing a broad-spectrum, host-directed therapy that is agnostic to the specific virus, which could be particularly valuable for pandemic preparedness and for vulnerable populations such as the elderly and immunocompromised.

Upcoming Catalysts (preview)

• Q1 2027Phase 2 clinical trial data readout40% success
• Q4 2026Strategic partnership or licensing deal50% success
• Q3 2026Series B funding round60% success